OTCMKTS:PKPH Peak Pharmaceuticals (PKPH) Stock Price, News & Analysis $0.87 -0.13 (-13.07%) As of 06/2/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Peak Pharmaceuticals Stock (OTCMKTS:PKPH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Peak Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.65▼$0.9550-Day Range$0.65▼$1.8752-Week Range$0.52▼$9.12Volume14,109 shsAverage Volume9,053 shsMarket Capitalization$340.77 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Peak Pharmaceuticals, Inc. manufactures and markets pharmaceutical level products containing phytocannabinoids, an abundant and pharmaceutically active component of industrial hemp for the prevention and alleviation of various conditions and diseases. The company was founded on December 18, 2007 and is headquartered in Scottsdale, AZ. Read More Receive PKPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Peak Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PKPH Stock News HeadlinesAkari Therapeutics Merges with Peak Bio for GrowthNovember 9, 2024 | markets.businessinsider.comNetflix hit series Wednesday season 2 is a ‘cultural juggernaut’ that’s already breaking recordsNovember 4, 2024 | msn.comStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed U.S. Treasury holdings by 45% from peak, and central banks are swapping dollars for gold at the fastest pace since the Cold War. Porter Stansberry believes Trump is channeling more than $3 trillion toward securing the minerals, chips, and infrastructure that make AI possible - and companies at those chokepoints like Vertiv (up 500%), GE Vernova (up 700%), and Arista Networks (up 750%) are already moving. Porter's new briefing names one asset to buy today plus five stocks positioned at the narrowest chokepoints of what he calls the Silicon Dollar.June 4 at 1:00 AM | Porter & Company (Ad)Phathom's Voquezna: A Breakthrough Drug Facing Marketing ChallengesSeptember 27, 2024 | seekingalpha.comThailand says mpox case recorded in traveller from AfricaAugust 22, 2024 | msn.comPharma stocks soar after WHO declares mpox public health emergencyAugust 20, 2024 | msn.comDaytime and early peak commissioningMay 2, 2024 | bbc.co.ukAkari Therapeutics Signs Merger-of-Equals with Peak BioMarch 5, 2024 | marketwatch.comSee More Headlines PKPH Stock Analysis - Frequently Asked Questions How have PKPH shares performed this year? Peak Pharmaceuticals' stock was trading at $1.6427 at the beginning of 2026. Since then, PKPH stock has decreased by 47.1% and is now trading at $0.8693. How do I buy shares of Peak Pharmaceuticals? Shares of PKPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Peak Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Peak Pharmaceuticals investors own include Ginkgo Bioworks (DNA), Jazz Pharmaceuticals (JAZZ), Medical Marijuana (MJNA), Altria Group (MO), OPKO Health (OPK), Growlife (PHOT) and RTX (RTX). Company Calendar Today6/04/2026Fiscal Year End9/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryCannabis Current SymbolOTCMKTS:PKPH CIK1452804 Webwww.peakpharma.com Phone(480) 659-6404FaxN/AEmployees1Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$160 thousand Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-159.55% Debt Debt-to-Equity RatioN/A Current Ratio0.15 Quick Ratio0.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares392,000Free Float320,000Market Cap$340.77 thousand OptionableNot Optionable Beta0.54 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (OTCMKTS:PKPH) was last updated on 6/4/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredA gold storm is coming – are you ready?The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...Traders Agency | SponsoredTrump’s New Dollar revealedThe last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe SpaceX S-1 changes everythingSpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...Crypto 101 Media | SponsoredHow to claim a stake in SpaceX before the June 12 IPOSpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...Brownstone Research | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Peak Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Peak Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.